Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2017

Open Access 01-12-2017 | Correspondence

Renal association clinical practice guideline in post-operative care in the kidney transplant recipient

Authors: Richard J. Baker, Patrick B. Mark, Rajan K. Patel, Kate K. Stevens, Nicholas Palmer

Published in: BMC Nephrology | Issue 1/2017

Login to get access

Abstract

These guidelines cover the care of patients from the period following kidney transplantation until the transplant is no longer working or the patient dies. During the early phase prevention of acute rejection and infection are the priority. After around 3–6 months, the priorities change to preservation of transplant function and avoiding the long-term complications of immunosuppressive medication (the medication used to suppress the immune system to prevent rejection). The topics discussed include organization of outpatient follow up, immunosuppressive medication, treatment of acute and chronic rejection, and prevention of complications. The potential complications discussed include heart disease, infection, cancer, bone disease and blood disorders. There is also a section on contraception and reproductive issues.
Immediately after the introduction there is a statement of all the recommendations. These recommendations are written in a language that we think should be understandable by many patients, relatives, carers and other interested people. Consequently we have not reworded or restated them in this lay summary. They are graded 1 or 2 depending on the strength of the recommendation by the authors, and AD depending on the quality of the evidence that the recommendation is based on.
Literature
1.
Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80:1383–91.PubMedCrossRef
2.
Adamu B, Abdu A, Abba AA, Borodo MM, Tleyjeh IM. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. Cochrane Database Syst Rev. 2014;3:CD008597.
3.
Allen U, Preiksaitis J, Practice ASTIDCo. Epstein-barr virus and posttransplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S87–96.PubMedCrossRef
4.
Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol. 2009;20:2490–2.PubMedCrossRef
5.
Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant. 2007;7:2748–56.PubMedCrossRef
6.
Amer H, Lieske JC, Rule AD, et al. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant. 2013;13:676–84.PubMedPubMedCentralCrossRef
7.
Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A. 2009;149A:1241–8.PubMedCrossRef
8.
Armenti VT, Daller JA, Constantinescu S, et al. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Clinical transplants. 2006:57–70.
9.
Asberg A, Humar A, Jardine AG, et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9:1205–13.PubMedCrossRef
10.
Beimler J, Zeier M. Borderline rejection after renal transplantation--to treat or not to treat. Clin Transpl. 2009;23 Suppl 21:19–25.CrossRef
11.
Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A, Oppenheimer F, Campistol JM. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation. 2008;86:413–7.PubMedCrossRef
12.
Bhaskaran K, Douglas I, Forbes H, Dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65.PubMedPubMedCentralCrossRef
13.
Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27:1471–9.PubMedPubMedCentralCrossRef
14.
Board JBS. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014;100 Suppl 2:ii1–67.CrossRef
15.
Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol. 2007;2 Suppl 1:S36–46.PubMedCrossRef
16.
Bohmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol. 2002;13:1091–9.PubMed
17.
Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, von Eckardstein A, Graf N, Wüthrich RP. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882–91.PubMedCrossRef
18.
Borchhardt K, Sulzbacher I, Benesch T, Fodinger M, Sunder-Plassmann G, Haas M. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Transplant. 2007;7:2515–21.PubMedCrossRef
19.
Bramham K, Nelson-Piercy C, Gao H, et al. Pregnancy in renal transplant recipients: a UK national cohort study. Clin J Am Soc Nephrol. 2013;8:290–8.PubMedCrossRef
20.
Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol. 2013;8:563–7.PubMedPubMedCentralCrossRef
21.
Brokhof MM, Sollinger HW, Hager DR, et al. Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibodies in moderately sensitized renal transplant recipients. Transplantation. 2014;97:612–7.PubMedPubMedCentralCrossRef
22.
BSHI/BTS. Guidelines for the detection and characterisation of clinically relevant antibodies in allotransplantation. 2014.
23.
BTS. Management of the Failing Kidney Transplant. 2013.
24.
BTS. Antibody Incompatible Transplantation Guideline. 2015.
25.
Buchanan C, Smith L, Corbett J, Nelson E, Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant. 2006;6:770–4.PubMedCrossRef
26.
Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377:837–47. doi:10.​1016/​S0140-6736(10)62318-5. Epub 2011 Feb 19.PubMedCrossRef
27.
Budde K, Lehner F, Sommerer C, et al. Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study. Am J Transplant. 2015;15:119–28. doi:10.​1111/​ajt.​12952. Epub 2014 Dec 17.PubMedCrossRef
28.
Butler JA, Peveler RC, Roderick P, Smith PW, Horne R, Mason JC. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant. 2004;19:3144–9.PubMedCrossRef
29.
Carpenter MA, Weir MR, Adey DB, House AA, Bostom AG, Kusek JW. Inadequacy of cardiovascular risk factor management in chronic kidney transplantation - evidence from the FAVORIT study. Clin Transpl. 2012;26:E438–46.CrossRef
30.
Chan K, Taube D, Roufosse C, et al. Kidney transplantation with minimized maintenance: alemtuzumab induction with tacrolimus monotherapy--an open label, randomized trial. Transplantation. 2011;92:774–80.PubMedCrossRef
31.
Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003;76:1289–93.PubMedCrossRef
32.
Cherukuri A, Welberry-Smith MP, Tattersall JE, et al. The clinical significance of early proteinuria after renal transplantation. Transplantation. 2010;89:200–7.PubMedCrossRef
33.
Chhabra D, Skaro AI, Leventhal JR, et al. Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Clin J Am Soc Nephrol. 2012;7:504–12.PubMedPubMedCentralCrossRef
34.
Choukroun G, Kamar N, Dussol B, et al. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360–8.PubMedPubMedCentralCrossRef
35.
Chow J, Golan Y. Vaccination of solid-organ transplantation candidates. Clin Infect Dis. 2009;49:1550–6.PubMedCrossRef
36.
37.
Collini A, De Bartolomeis C, Barni R, Ruggieri G, Bernini M, Carmellini M. Calcineurin-inhibitor induced pain syndrome after organ transplantation. Kidney Int. 2006;70:1367–70.PubMedCrossRef
38.
Collins AJ, Foley RN, Chavers B, et al. US Renal Data System 2013 Annual Data Report. Am J Kidney Dis. 2014;63:A7.PubMedCrossRef
39.
Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol. 1997;8:1930–41.PubMed
40.
41.
Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2010:65–85.
42.
Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation. 2010;90:695–704.PubMedCrossRef
43.
44.
Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation. 1999;68:1859–64.PubMedCrossRef
45.
de Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol. 2001;12:1538–46.PubMed
46.
Dharnidharka VR, Cherikh WS, Neff R, Cheng Y, Abbott KC. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant. 2010;10:1312–5.PubMedCrossRef
47.
Do H. Achieving Excellence in Kidney Care: Delivering the National Service Framework for Renal Services. 2009.
48.
Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4:2082–92.PubMedCrossRef
49.
Drueke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int. 2012;82:952–60.PubMedCrossRef
50.
Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the “creeping creatinine” study. Transplantation. 2005;79:466–75.PubMedCrossRef
51.
Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. The Cochrane database of systematic reviews. 2007:CD004659.
52.
Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–44.PubMedPubMedCentralCrossRef
53.
Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007;357:2562–75.PubMedCrossRef
54.
Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9:1876–85.PubMedCrossRef
55.
Elder GJ. From marrow oedema to osteonecrosis: common paths in the development of post-transplant bone pain. Nephrology. 2006;11:560–7.PubMedCrossRef
56.
El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant. 2009;9:527–35.PubMedCrossRef
57.
Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med. 2012;367:329–39.PubMedCrossRef
58.
Evans S, Michael R, Wells H, et al. Drug interaction in a renal transplant patient: cyclosporin-Neoral and orlistat. Am J Kidney Dis. 2003;41:493–6.PubMedCrossRef
59.
Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant. 2005;20:1714–20.PubMedCrossRef
60.
Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation. 2013;95:410–7.PubMedCrossRef
61.
Excellence NIfC. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy (clinical guideline 107). 2010.
62.
Filocamo MT, Zanazzi M, Li Marzi V, et al. Sexual dysfunction in women during dialysis and after renal transplantation. J Sex Med. 2009;6:3125–31.PubMedCrossRef
63.
Fox BC, Sollinger HW, Belzer FO, Maki DG. A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med. 1990;89:255–74.PubMedCrossRef
64.
Garg S, Carroll RP, Walker RG, Ramsay HM, Harden PN. Skin cancer surveillance in renal transplant recipients: re-evaluation of U.K. practice and comparison with Australian experience. Br J Dermatol. 2009;160:177–9.PubMedCrossRef
65.
Gaynor JJ, Ciancio G, Guerra G, et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. Transpl Int. 2016;29:216–26.PubMedCrossRef
66.
Gray D, Shepherd H, Daar A, Oliver DO, Morris PJ. Oral versus intravenous high-dose steroid treatment of renal allograft rejection. The big shot or not? Lancet. 1978;1:117–8.PubMedCrossRef
67.
Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82:1052–9.PubMedCrossRef
68.
Grinyo JM, Saval N, Campistol JM, Group IS. Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients. Nephrol Dial Transplant. 2011;26:3750–5.PubMedCrossRef
69.
Grotz WH, Breitenfeldt MK, Braune SW, et al. Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation. Transpl Int. 2001;14:16–23.PubMedCrossRef
70.
Group CSC, Haynes R, Harden P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384:1684–90.CrossRef
71.
Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–83.PubMedCrossRef
72.
Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant. 2005;5:2281–8.PubMedCrossRef
73.
Hanaway MJ, Woodle ES, Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation. N Engl J Med. 2011;364:1909–19.PubMedCrossRef
74.
Harden PN, Fryer AA, Reece S, Smith AG, Ramsay HM. Annual incidence and predicted risk of nonmelanoma skin cancer in renal transplant recipients. Transplant Proc. 2001;33:1302–4.PubMedCrossRef
75.
Hardinger KL, Koch MJ, Bohl DJ, Storch GA, Brennan DC. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant. 2010;10:407–15.PubMedPubMedCentralCrossRef
76.
77.
Health Information for overseas travel - Department of Health. 2015.
78.
79.
Heiwe S, Jacobson SH. Exercise Training in Adults With CKD: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2014;64:383–93.PubMedCrossRef
80.
Hellemans R, Hazzan M, Durand D, et al. Daclizumab versus rabbit antithymocyte globulin in high-risk renal transplants: five-year follow-up of a randomized study. Am J Transplant. 2015;15:1923–32.PubMedCrossRef
81.
Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9:2532–41.PubMedCrossRef
82.
Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347:488–96.PubMedCrossRef
83.
Hirsch HH, Randhawa P, Practice ASTIDCo. BK virus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S136–46.PubMedCrossRef
84.
Ho J, Wiebe C, Gibson IW, Rush DN, Nickerson PW. Immune monitoring of kidney allografts. Am J Kidney Dis. 2012;60:629–40.PubMedCrossRef
85.
Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet. 2005;365:2105–15.PubMedCrossRef
86.
Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361:2024–31.PubMedCrossRef
87.
Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant. 2005;5:2929–36.PubMedCrossRef
88.
Humar A, Gillingham K, Kandaswamy R, Payne W, Matas A. Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant. 2007;7:1948–53.PubMedCrossRef
89.
Humar A, Snydman D, Practice ASTIDCo. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S78–86.PubMedCrossRef
90.
Humar A, Asberg A, Kumar D, et al. An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant. 2009;9:374–81.PubMedCrossRef
91.
Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant. 2010;10:1228–37.PubMedCrossRef
92.
Hurst FP, Altieri M, Patel PP, et al. Effect of smoking on kidney transplant outcomes: analysis of the United States Renal Data System. Transplantation. 2011;92:1101–7.PubMedCrossRef
93.
Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis. 2005;46:529–36.PubMedCrossRef
94.
Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet. 2011;378:1419–27.PubMedCrossRef
95.
Johnston O, Jaswal D, Gill JS, Doucette S, Fergusson DA, Knoll GA. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation. 2010;89:1057–70.PubMedCrossRef
96.
Josephson MA, Schumm LP, Chiu MY, Marshall C, Thistlethwaite JR, Sprague SM. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation. 2004;78:1233–6.PubMedCrossRef
97.
Kadakia KC, Barton DL, Loprinzi CL, et al. Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251). Cancer. 2012;118:2128–37.PubMedCrossRef
98.
Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation. 2001;72:1181–93.PubMedCrossRef
99.
Kahan BD, Welsh M, Urbauer DL, et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol. 2000;11:1122–31.PubMed
100.
Kandil E, Florman S, Alabbas H, et al. Exploring the effect of parathyroidectomy for tertiary hyperparathyroidism after kidney transplantation. Am J Med Sci. 2010;339:420–4.PubMedPubMedCentralCrossRef
101.
Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation. 2005;80:883–9.PubMedCrossRef
102.
Kedainis RL, Koch MJ, Brennan DC, Liapis H. Focal C4d + in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival. Am J Transplant. 2009;9:812–9.PubMedPubMedCentralCrossRef
103.
Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transpl. 2009;23:800–6.CrossRef
104.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–155.
105.
Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1–155.
106.
Kirk AD, Cherikh WS, Ring M, et al. Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab. Am J Transplant. 2007;7:2619–25.PubMedPubMedCentralCrossRef
107.
Knight SR, Morris PJ. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation. 2008;85:1675–85.PubMedCrossRef
108.
109.
Knoll GA, Fergusson D, Chasse M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol. 2015.
110.
Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333–60.PubMedCrossRef
111.
Kovarik JM, Tedesco H, Pascual J, et al. Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation. Ther Drug Monit. 2004;26:499–505.PubMedCrossRef
112.
Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant. 2009;9:1826–34.PubMedCrossRef
113.
Kumar D, Unger ER, Panicker G, Medvedev P, Wilson L, Humar A. Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant. 2013;13:2411–7.PubMedPubMedCentralCrossRef
114.
Kuypers DR, Bammens B, Claes K, Evenepoel P, Vanrenterghem Y. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. Transplantation. 2010;89:1296–7. author reply 7–8.PubMedCrossRef
115.
Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation. 2009;87:1505–13.PubMedCrossRef
116.
Langone A, Steinberg SM, Gedaly R, et al. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrO (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transpl. 2015;29:796–805.CrossRef
117.
Lee J, Huh KH, Park Y, et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2015.
118.
Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant. 2009;9:1099–107.PubMedCrossRef
119.
Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005;16:496–506.PubMedCrossRef
120.
Lentine KL, Schnitzler MA, Xiao H, Brennan DC. Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10–10 Study participants. Trials. 2015;16:365.PubMedPubMedCentralCrossRef
121.
Lim W, Chadban S, Campbell S, Dent H, Russ G, McDonald S. Effect of interleukin-2 receptor antibody therapy on acute rejection risk and severity, long-term renal function, infection and malignancy-related mortality in renal transplant recipients. Transpl Int. 2010;23:1207–15.PubMedCrossRef
122.
Lo P, Sharma A, Craig JC, et al. Preconditioning Therapy in ABO-Incompatible Living Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation. 2015.
123.
Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9:231–5.PubMedCrossRef
124.
Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013;369:1215–26.PubMedCrossRef
125.
Lowance D, Neumayer HH, Legendre CM, et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med. 1999;340:1462–70.PubMedCrossRef
126.
Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol. 2009;20:2449–58.PubMedPubMedCentralCrossRef
127.
Machnicki G, Pinsky B, Takemoto S, et al. Predictive ability of pretransplant comorbidities to predict long-term graft loss and death. Am J Transplant. 2009;9:494–505.PubMedCrossRef
128.
Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab as induction therapy in renal transplantation. Transplant Rev. 2015;29:103–8.CrossRef
129.
Mactier R, Davies S, Dudley C, et al. Summary of the 5th edition of the renal association clinical practice guidelines (2009–2012). Nephron Clin Pract. 2011;118 Suppl 1:c27–70.PubMedCrossRef
130.
Maggiore U, Medici MC, Vaglio A, Buzio C. Increased viral load after intravenous immunoglobulin therapy for BK virus-associated nephropathy. Transpl Infect Dis. 2010;12:470–2.PubMedCrossRef
131.
Malavaud B, Rostaing L, Rischmann P, Sarramon JP, Durand D. High prevalence of erectile dysfunction after renal transplantation. Transplantation. 2000;69:2121–4.PubMedCrossRef
132.
Maluf DG, Dumur CI, Suh JL, et al. The urine microRNA profile may help monitor post-transplant renal graft function. Kidney Int. 2014;85:439–49.PubMedCrossRef
133.
Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007;7:864–71.PubMedCrossRef
134.
Massey EK, Tielen M, Laging M, et al. The role of goal cognitions, illness perceptions and treatment beliefs in self-reported adherence after kidney transplantation: a cohort study. J Psychosom Res. 2013;75:229–34.PubMedCrossRef
135.
136.
Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant. 2005;5:2473–8.PubMedCrossRef
137.
Matas AJ, Gillingham K, Kandaswamy R, et al. Kidney transplant half-life (t[1/2]) after rapid discontinuation of prednisone. Transplantation. 2009;87:100–2.PubMedPubMedCentralCrossRef
138.
Matoza JR, Danguilan RA, Chicano S. Impact of Banff borderline acute rejection among renal allograft recipients. Transplant Proc. 2008;40:2303–6.PubMedCrossRef
139.
McKay DB, Josephson MA. Pregnancy in recipients of solid organs--effects on mother and child. N Engl J Med. 2006;354:1281–93.PubMedCrossRef
140.
Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol. 2004;15:3233–9.PubMedCrossRef
141.
Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant. 2002;2:807–18.PubMedCrossRef
142.
143.
Morken NH, Diaz-Garcia C, Reisaeter AV, et al. Obstetric and neonatal outcome of pregnancies fathered by males on immunosuppression after solid organ transplantation. Am J Transplant. 2015;15:1666–73.PubMedCrossRef
144.
Morrissey PE, Gohh R, Shaffer D, et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation. 1997;63:845–8.PubMedCrossRef
145.
Mycophenolate Mofetil Acute Renal Rejection Study G. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: three-year follow-up. The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation. 2001;71:1091–7.CrossRef
146.
147.
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation. 2004;78:242–9.PubMedCrossRef
148.
149.
Nicholson ML, Wheatley TJ, Doughman TM, et al. A prospective randomized trial of three different sizes of core-cutting needle for renal transplant biopsy. Kidney Int. 2000;58:390–5.PubMedCrossRef
150.
Nicoletto BB, Fonseca NK, Manfro RC, Goncalves LF, Leitao CB, Souza GC. Effects of obesity on kidney transplantation outcomes: a systematic review and meta-analysis. Transplantation. 2014;98:167–76.PubMedCrossRef
151.
Norrman E, Bergh C, Wennerholm UB. Pregnancy outcome and long-term follow-up after in vitro fertilization in women with renal transplantation. Hum Reprod. 2015;30:205–13.PubMedCrossRef
152.
153.
O’Grady JG, Asderakis A, Bradley R, et al. Multidisciplinary insights into optimizing adherence after solid organ transplantation. Transplantation. 2010;89:627–32.PubMedCrossRef
154.
Opelz G, Dohler B. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers. Transplantation. 2014;97:310–5.PubMedCrossRef
155.
Pallet N, Burgard M, Quamouss O, et al. Cidofovir may be deleterious in BK virus-associated nephropathy. Transplantation. 2010;89:1542–4.PubMedCrossRef
156.
Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998;113:1215–24.PubMedCrossRef
157.
Parker R, Armstrong MJ, Corbett C, Day EJ, Neuberger JM. Alcohol and substance abuse in solid-organ transplant recipients. Transplantation. 2013;96:1015–24.PubMedCrossRef
158.
Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med. 2002;346:580–90.PubMedCrossRef
159.
Paulen ME, Folger SG, Curtis KM, Jamieson DJ. Contraceptive use among solid organ transplant patients: a systematic review. Contraception. 2010;82:102–12.PubMedCrossRef
160.
161.
Peters B, Andersson Y, Stegmayr B, et al. A study of clinical complications and risk factors in 1,001 native and transplant kidney biopsies in Sweden. Acta Radiol. 2014;55:890–6.PubMedCrossRef
162.
Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–32.PubMedCrossRef
163.
Pilch NA, Taber DJ, Moussa O, et al. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation. Ann Surg. 2014;259:888–93.PubMedCrossRef
164.
Pilmore HL, Skeans MA, Snyder JJ, Israni AK, Kasiske BL. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation. 2011;91:542–51.PubMedCrossRef
165.
Ponticelli C. Basiliximab: efficacy and safety evaluation in kidney transplantation. Expert Opin Drug Saf. 2014;13:373–81.PubMedCrossRef
166.
Prendergast MB, Gaston RS. Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation. Clin J Am Soc Nephrol. 2010;5:1305–11.PubMedPubMedCentralCrossRef
167.
Qureshi F, Rabb H, Kasiske BL. Silent acute rejection during prolonged delayed graft function reduces kidney allograft survival. Transplantation. 2002;74:1400–4.PubMedCrossRef
168.
Raggi MC, Siebert SB, Friess H, Schremmer-Danninger E, Thorban S, Dinkel A. Sexual and relationship functioning before and after renal transplantation: a descriptive study with patients and partners. Scand J Urol Nephrol. 2012;46:431–6.PubMedCrossRef
169.
Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009;87:621–30.PubMedCrossRef
170.
Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation. 2007;84:437–9.PubMedCrossRef
171.
Randhawa PS, Schonder K, Shapiro R, Farasati N, Huang Y. Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation. 2010;89:1462–5.PubMedPubMedCentralCrossRef
172.
Razonable RR, Zerr DM, Practice ASTIDCo. HHV-6, HHV-7 and HHV-8 in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S97–100.PubMedCrossRef
173.
Reece SM, Harden PN, Smith AG, Ramsay HM. A model for nurse-led skin cancer surveillance following renal transplantation. Nephrol Nurs J. 2002;29:257–9. 67.PubMed
174.
Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am J Transplant. 2012;12:1975–82.PubMedCrossRef
175.
Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015;11:98–109.PubMedCrossRef
176.
Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94:775–83.PubMedCrossRef
177.
Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study. Am J Transplant. 2013;13:2875–83. doi:10.​1111/​ajt.​12460. Epub 2013 Sep 18.PubMedCrossRef
178.
Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3:79–87.PubMedCrossRef
179.
Rowshani AT, Scholten EM, Bemelman F, et al. No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. J Am Soc Nephrol. 2006;17:305–12.PubMedCrossRef
180.
Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7:2538–45.PubMedCrossRef
181.
SaBTO/BSBMT. Reducing the risk of Transfusion-transmitted Hepatitis E Virus (HEV) infections in patients undergoing Solid Organ Transplantation (SOT) and Haematopoietic Stem Cell Transplantation (HSCT). 2016.
182.
SaBTO/BSBMT. SaBTO Letter to Clinicians - Re Hep E Virus. 2016.
183.
Salgo R, Gossmann J, Schofer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385–93.PubMedCrossRef
184.
Sapir-Pichhadze R, Wang Y, Famure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. Kidney Int. 2014;85:1404–11.PubMedCrossRef
185.
Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87:233–42.PubMedCrossRef
186.
Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–99.PubMedCrossRef
187.
Serra AL, Braun SC, Starke A, et al. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008;8:803–10.PubMedCrossRef
188.
Sezai A, Soma M, Nakata KI, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients with chronic kidney disease (NU-FLASH trial for CKD). J Cardiol. 2015;66(4):289–303.CrossRef
189.
Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone vs tacrolimus/prednisone/mycophenolate mofetil in renal transplantation: 1-year actuarial follow-up. Transplant Proc. 1999;31:1134.PubMedPubMedCentralCrossRef
190.
Sharma RK, Prasad N, Gupta A, Kapoor R. Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. Am J Kidney Dis. 2006;48:128–33.PubMedCrossRef
191.
Shehata M, Bhandari S, Venkat-Raman G, et al. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation. Transpl Int. 2009;22:821–30.PubMedCrossRef
192.
Shinn C, Malhotra D, Chan L, Cosby RL, Shapiro JI. Time course of response to pulse methylprednisolone therapy in renal transplant recipients with acute allograft rejection. Am J Kidney Dis. 1999;34:304–7.PubMedCrossRef
193.
Short CD, Russell S, Valentine A. Clinical audit and long-term evaluation of renal transplant recipients. Transplantation. 2001;72:S94–8.PubMed
194.
Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82:1698–702.PubMedCrossRef
195.
Sofue T, Inui M, Hara T, et al. Efficacy and safety of febuxostat in the treatment of hyperuricemia in stable kidney transplant recipients. Drug Des Devel Ther. 2014;8:245–53.PubMedPubMedCentralCrossRef
196.
Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–60.PubMedCrossRef
197.
Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellstrom B. A cardiovascular risk calculator for renal transplant recipients. Transplantation. 2012;94:57–62.PubMedCrossRef
198.
Srinivas TR, Schold JD, Womer KL, et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:323–6.PubMedCrossRef
199.
Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005;352:1317–23.PubMedCrossRef
200.
Stasko T, Brown MD, Carucci JA, et al. Guidelines for the management of squamous cell carcinoma in organ transplant recipients. Dermatol Surg. 2004;30:642–50.PubMed
201.
Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: Are some statins safer than others? Nephrol Dial Transplant. 2001;16:873–4.PubMedCrossRef
202.
Sun Q, Liu ZH, Yin G, et al. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients. Nephrol Dial Transplant. 2006;21:510–7.PubMedCrossRef
203.
Sun Q, Liu ZH, Cheng Z, et al. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil. Kidney Int. 2007;71:24–30.PubMedCrossRef
204.
Tait BD, Susal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95:19–47.PubMedCrossRef
205.
Tojimbara T, Nakajima I, Yashima J, Fuchinoue S, Teraoka S. Efficacy and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in kidney transplant recipients. Transplant Proc. 2014;46:511–3.PubMedCrossRef
206.
Tong A, Howell M, Wong G, Webster AC, Howard K, Craig JC. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant. 2011;26:344–54.PubMedCrossRef
207.
Torres A, Garcia S, Gomez A, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 2004;65:705–12.PubMedCrossRef
208.
Turk TR, Voropaeva E, Kohnle M, et al. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008;23:369–73.PubMedCrossRef
209.
Tutone VK, Mark PB, Stewart GA, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transpl. 2005;19:181–92.CrossRef
210.
Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;70:2058–65.PubMedCrossRef
211.
UK KR. Kidney Health Delivering Excellence. 2013.
212.
van der Beek MT, Berger SP, Vossen AC, et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation. 2010;89:320–6.PubMedCrossRef
213.
van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant. 2009;9:1495–9.PubMedCrossRef
214.
van Gelder T. Within-patient variability in immunosuppressive drug exposure as a predictor for poor outcome after transplantation. Kidney Int. 2014;85:1267–8.PubMedCrossRef
215.
Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353:770–81.PubMedCrossRef
216.
Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant. 2007;7:1506–14.PubMedCrossRef
217.
Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int. 2003;63:1187–94.PubMedCrossRef
218.
Wadei HM, Textor SC. Hypertension in the kidney transplant recipient. Transplant Rev (Orlando). 2010;24(3):105–20.CrossRef
219.
Wagner M, Earley AK, Webster AC, Schmid CH, Balk EM, Uhlig K. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev. 2015;12:CD007746.
220.
Watnick S, Rueda J. Reproduction and contraception after kidney transplantation. Curr Opin Obstet Gynecol. 2008;20:308–12.PubMedCrossRef
221.
Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331:810.PubMedPubMedCentralCrossRef
222.
Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation. 2006;81:1234–48.PubMedCrossRef
223.
Webster AC, Pankhurst T, Rinaldi F, Chapman JR, Craig JC. Monoclonal and polyclonal antibody therapy for treating acute rejection in kidney transplant recipients: a systematic review of randomized trial data. Transplantation. 2006;81:953–65.PubMedCrossRef
224.
225.
Welberry Smith MP, Cherukuri A, Newstead CG, et al. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial. Transplantation. 2013;96:1082–8.PubMedCrossRef
226.
Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157–67.PubMedCrossRef
227.
228.
Wong G, Howard K, Webster A, Chapman JR, Craig JC. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation. 2009;87:1078–91.PubMedCrossRef
229.
Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg. 2008;248:564–77.PubMed
230.
Woodward RS, Schnitzler MA, Baty J, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipient. Am J Transplant. 2003;3:590–8.PubMedCrossRef
231.
Wu K, Budde K, Lu H, et al. The severity of acute cellular rejection defined by Banff classification is associated with kidney allograft outcomes. Transplantation. 2014;97:1146–54.PubMedCrossRef
232.
Yildiz A, Cine N, Akkaya V, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation. 2001;72:542–4.PubMedCrossRef
233.
Zitt E, Woess E, Mayer G, Lhotta K. Effect of cinacalcet on renal electrolyte handling and systemic arterial blood pressure in kidney transplant patients with persistent hyperparathyroidism. Transplantation. 2011;92:883–9.PubMedCrossRef
Metadata
Title
Renal association clinical practice guideline in post-operative care in the kidney transplant recipient
Authors
Richard J. Baker
Patrick B. Mark
Rajan K. Patel
Kate K. Stevens
Nicholas Palmer
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2017
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-017-0553-2

Other articles of this Issue 1/2017

BMC Nephrology 1/2017 Go to the issue

Research article

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

Research article

How does pre-dialysis education need to change? Findings from a qualitative study with staff and patients

Research article

Erythropoiesis stimulating agents and reno-protection: a meta-analysis

Research article

MDRD vs. CKD-EPI in comparison to 51Chromium EDTA: a cross sectional study of Malaysian CKD cohort

Research article

Factors associated with foot ulceration and amputation in adults on dialysis: a cross-sectional observational study

Research article

Strategies and cost-effectiveness evaluation of persistent albuminuria screening among high-risk population of chronic kidney disease

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits